KRAS alterations, which were one of the few genomic associations with improved PFS, associated with a history of tobacco exposure, adenocarcinoma histology, and trended toward higher PD-L1 expression in the MDACC-primary cohort, consistent with a more ICI-responsive clinical phenotype (Supplementary Table 1). This evidence concerns the gene CD274 and adenocarcinoma.